Cancer risk cut in half
GLP-1 receptor agonist drugs, including Ozempic, Wegovy, and Mounjaro, slash the risk of four types of cancer by 50% or more, according to a new study reported by Medical News Today. The research analyzed patient outcomes across multiple health databases and found dramatic reductions in obesity-related cancers, particularly among patients who took the medications consistently for more than one year.
FDA proposes crackdown on compounding
The FDA proposed a ban on bulk compounding of semaglutide and tirzepatide, the active ingredients in blockbuster weight loss and diabetes drugs. Compounding pharmacies have been producing cheaper, unapproved versions of these medications amid ongoing shortages, raising safety concerns about dosing errors and contamination.
First AI-designed vaccine tested in humans
In a world first, a vaccine designed entirely by artificial intelligence has entered human clinical trials. The AI-designed vaccine targets a challenging viral pathogen and was developed in a fraction of the time of traditional vaccine development. Early results are expected later this year, and success could usher in a new era of AI-accelerated drug discovery.